Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04482660 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 31, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Site details revised
    v7
  2. Primary completion date: Mar 31, 2024 to Dec 31, 2024
    • Study completion date: Mar 31, 2025 to Dec 31, 2025
    v6
  3. 2 versions Re-verified since Sep 14, 2021, no change to tracked fieldsv4-v5
  4. Start date changed from estimate of Oct 2020 to Mar 29, 2021
    • Primary completion date: Oct 2023 to Mar 31, 2024
    • Study completion date: Oct 2024 to Mar 31, 2025
    v3
  5. Study Identification, Study Statusv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.
Trial Details
NCT Number NCT04482660
Lead Sponsor Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborators: Hoffmann-La Roche, Hospital Clinic of Barcelona
Conditions
(from sponsor)		 Healthy, Mild Cognitive Impairment
Related terms Cognitive Dysfunction
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov